Statins for the prevention of dementia

  • Conclusions changed
  • Review
  • Intervention




This is an update of a Cochrane review first published in 2001. At that stage there was insufficient evidence to recommend statins for the prevention of Alzheimer's disease (AD). The scope of this review has been expanded to include all forms of dementia.


To assess the effects of statins in the prevention of dementia.

Search methods

The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched on 10 October 2007 using the terms statin*, lovastatin*, pravastatin*, simvastatin*, fluvastatin*, atorvastatin* and rosuvastatin*. The CDCIG Register contains records from many healthcare databases, SIGLE, LILACS as well as many trials databases and is updated regularly.

Selection criteria

Double-blind randomized placebo-controlled trials of statins in people at risk of AD and dementia.

Data collection and analysis

Two independent reviewers extracted and assessed data independently and agreement was reached after discussion. Adverse effects were noted.

Main results

Two trials were identified with 26,340 participants; HPS 2002 and PROSPER 2002. Age range was 40-82 years across the two studies, PROSPER 2002 included 5804 patients aged 70-82 years and HPS included 20,536 patients with 5806 at least 70 years old at study entry. Mean total cholesterol 5.9 mmol/l, LDL cholesterol 3.4mmol/l at study entry with mean reduction in LDL cholesterol of 1.0mmol/l in simvastatin treated patients compared to placebo in HPS 2002. Mean total cholesterol 5.7mmol/l, LDL cholesterol 3.8 mmol/l at study entry with mean reduction in LDL cholesterol of 1.02 mmol/l in pravastatin treated patients compared to placebo in PROSPER 2002. Mean follow-up 3.2 years in PROSPER, 5 years in HPS 2002. Cognition was measured at different times and with different scales so could not be combined in a meta-analysis. There was no difference in incidence of dementia in HPS 2002 (31 cases in simvastatin group, 31 cases in placebo group) nor in performance on the modified Telephone Interview for Cognitive Status at final follow-up (23.7% simvastatin group cognitively impaired vs 24.2% in placebo group). There was no difference in cognition between groups either in relation to age at study entry or previous history of cerebrovascular disease. Cognitive function declined at the same rate in both treatment groups in PROSPER 2002, there was no significant difference between pravastatin treated and placebo groups in performance on letter digit codes, picture word learning test, Stroop and Mini Mental State Examination. There was no evidence that statins were detrimental to cognition.

Authors' conclusions

There is good evidence from RCTs that statins given in late life to individuals at risk of vascular disease have no effect in preventing AD or dementia. Biologically it seems feasible that statins could prevent dementia due to their role in cholesterol reduction and initial evidence from observational studies was very promising. Indication bias may have been a factor in these studies however and the evidence from subsequent RCTs has been negative.








2007年10月10日に、用語statin*(スタチン)、lovastatin*(ロバスタチン)、pravastatin*(プラバスタチン)、simvastatin*(シンバスタチン)、fluvastatin*(フルバスタチン)、atorvastatin*(アトルバスタチン)、rosuvastatin*(ロスバスタチン)を用いて、Specialized Register of the Cochrane Dementia and Cognitive Improvement Group、コクラン・ライブラリ、MEDLINE、EMBASE、PsycINFO、CINAHLおよびLILACSを検索した。CDCIG Registerには、多数の試験データベースからの記録に加え、多数の保健医療データベース、SIGLE、LILACSが含まれ、定期的に更新されている。






参加者26,340例を対象とした2件の試験、HPS 2002およびPROSPER 2002を同定した。2件の研究全体の年齢範囲は40~82歳であり、PROSPER 2002は年齢70~82歳の患者5,804例を対象としており、HPSは研究登録時に70歳以上であった5,806例を含む患者20,536例を対象としていた。HPS 2002では、研究登録時の平均総コレステロールは5.9 mmol/L、LDL-コレステロールは3.4mmol/Lであり、シンバスタチン治療患者ではプラセボと比較してLDL-コレステロールが平均1.0mmol/L低下した。PROSPER 2002では、研究登録時の平均総コレステロールは5.7mmol/L、LDL-コレステロールは3.8mmol/Lであり、プラバスタチン治療患者ではプラセボと比較してLDL-コレステロールが平均1.02mmol/L低下した。PROSPERの平均追跡期間は3.2年、HPS 2002では5年であった。認知については、異なる時点で異なる尺度で測定されていたためメタアナリシスに統合することはできなかった。HPS 2002では、認知症の罹患率に差はなく(シンバスタチン群31例、プラセボ群31例)、最終追跡時のmodified Telephone Interview for Cognitive Statusによる成績にも差はなかった(シンバスタチン群では23.7%に認知障害があったのに対しプラセボ群では24.2%であった)。研究登録時の年齢や脳血管障害の既往歴に関連した認知に群間で差を認めなかった。PROSPER 2002では、両治療群の認知機能は同程度の進行度で低下しており、letter digit code、picture word learning test(絵画語彙学習テスト)、StroopおよびMini Mental State Examinationによる成績については、プラバスタチン群とプラセボ群との間で有意差はなかった。スタチン系が認知に不利益となることを示すエビデンスはなかった。




監  訳: 大神 英一,2009.9.15

実施組織: 厚生労働省委託事業によりMindsが実施した。

ご注意 : この日本語訳は、臨床医、疫学研究者などによる翻訳のチェックを受けて公開していますが、訳語の間違いなどお気づきの点がございましたら、Minds事務局までご連絡ください。Mindsでは最新版の日本語訳を掲載するよう努めておりますが、編集作業に伴うタイム・ラグが生じている場合もあります。ご利用に際しては、最新版(英語版)の内容をご確認ください。

Plain language summary

There good evidence that statins given in late life to individuals at risk of vascular disease have no effect in preventing dementia

Evidence accumulating from biological and epidemiological studies suggest that high levels of serum cholesterol may promote the pathological processes that lead to Alzheimer's disease. Lowering cholesterol in experimental animal models slows the expression of Alzheimer's pathology. These findings raise the possibility that treating humans with cholesterol lowering medications might reduce the risk of developing Alzheimer's disease. The statin family of medications (lovastatin, pravastatin,simvastatin, and others) are powerful cholesterol lowering agents of proven benefit in vascular disease. Several clinical studies comparing the occurrence of Alzheimer's disease between users of statins and non-users of statins suggest that risk of Alzheimer's disease is substantially reduced among the users. However, because these studies are not randomized trials, they provide insufficient evidence to recommend statin therapy. Two randomized trials have since been carried out and neither showed any reduction in occurrence of AD or dementia in patients treated with statins compared to those given placebo. Statins cannot therefore be recommended for the prevention of AD or dementia.